1

HIV and AIDS Articles by Topic - A to Z  

 Google Custom Search
Studies Examine Unprotected Sex, Serosorting, and Circumcision among Men Who Have Sex with Men in the U.S.
 
By Liz Highleyman

Amid news that the U.S. Centers for Disease Control nd Prevention (CDC) will likely soon release higher figures for estimated annual HIV infections, several recent studies have looked at HIV transmission and prevention among men who have sex with men (MSM), who continue to bear the brunt of the epidemic in the U.S.

HIV Incidence and Risk Factors among Black MSM

At the 2007 National HIV Prevention Conference last week in Atlanta (December 2-5), researchers reported on rates of HIV transmission and risk factors among black MSM.

Studies have shown that black MSM are about twice as likely as white MSM to be HIV positive, and may be as much as 7 times more likely to become newly infected. According to an analysis presented at the conference, young black MSM have experienced the largest recent increase in new HIV diagnoses.

Based on data from the U.S. National HIV/AIDS Reporting System, Joseph Prejean from the CDC and colleagues (abstract B08-5) found that black MSM born in the 1965-1969 period had a high but stable rate of new HIV infections between 2001 and 2005, while those born in 1975-1979 or 1980-1984 experienced a rising rate. (Importantly, this analysis is based on data from the 33 states with long-term names-based HIV reporting, which excludes some areas with the highest estimated HIV rates.)

However, the reasons for the higher HIV incidence rate among black MSM are unclear, since they do not appear more likely to engage in high-risk behavior. 

Gregorio Millett and colleagues from the CDC (abstract A03-1) conducted a systematic review of 53 studies published between 1980 and 2006, which included a total of more than 60,000 MSM.

Overall, the studies showed that black MSM were not more likely to engage in unprotected receptive sex (including anal intercourse) or to use illicit drugs (including marijuana, poppers, methamphetamine, cocaine, or opiates) compared with their white counterparts. In fact, data indicated that young black MSM were less likely to have unprotected anal sex or to use drugs than white MSM of the same age group.

However, breaking down the data by time period showed that black MSM did have higher rates than whites of high-risk sexual behavior in the early years of the epidemic (1980-1990), although this difference was no longer present by the middle (1991-2000) and late (2001-2006) periods.

Millett suggested that the difference in risk behavior early in the epidemic allowed more black MSM to become infected, and the group continues to have a higher rate of new infections since many MSM tend to have sex and use drugs primarily with people of the same race/ethnicity.

In other words, a black man who only has sex with other black men faces a higher likelihood of encountering HIV positive partners than a white man who only has sex with other white men, and thus is at greater risk of infection even if he engage in exactly the same activities.

Millet also suggested -- based on recent evidence indicating that black MSM may be less likely than white MSM to know their HIV status or to be taking antiretroviral therapy -- that black HIV positive men may be more likely to have a higher viral load, which facilitates HIV transmission. Further, black MSM have higher rates of other sexually transmitted diseases (such as syphilis), which can increase the risk of both transmitting and contracting HIV.

Circumcision in the U.S.
Recent studies indicating that adult male circumcision is associated with significantly lower rates of HIV infection among primarily heterosexual men in sub-Saharan Africa have raised questions about whether this might also hold true in areas such as the U.S. and Europe where the overall HIV prevalence rate is much lower.

Millett presented data at the Atlanta conference (abstract C01-4) on the link between circumcision status and HIV infection among black and Latino MSM in 3 U.S. cities. The study results were also published in the December 15, 2007 Journal of Acquired Immune Deficiency Syndromes.

Using respondent-driven sampling, the investigators recruited 1154 black MSM and 1091 Latino MSM in Los Angeles, New York City, and Philadelphia who completed a 45-minute computer-assisted interview and took a rapid oral fluidHIV antibody test.

The researchers found that black men were more than twice as likely as Latino men to have been circumcised (74% vs 33%); they did not report rates among white MSM. Circumcised men in both racial/ethnic groups were more likely than uncircumcised men to have been born in the U.S. or to have a U.S.-born parent. In the U.S., the overall rate of infant circumcision is thought to have peaked at around 85% in the mid-1960s; the practice is uncommon in the Latin American countries many U.S. Latinos or their families came from.

Circumcision status was not significantly associated with either a higher or lower prevalence of HIV infection among black or Latino MSM; this was also true for black and Latino men who reported being HIV negative based on their last HIV test. In addition, circumcision was not associated with a decreased risk of HIV infection among black MSM who recently had sex with women, or those who reported only unprotected insertive but not receptive anal sex (the ones most likely to experience a protective benefit from circumcision).

Based on this cross-sectional data, the investigators concluded, “there was no evidence that being circumcised was protective against HIV infection among black MSM or Latino MSM.”
Serosorting
Finally, Lisa Eaton and colleagues presented data on serosorting among MSM in the December 2007 American Journal of Preventive Medicine. Serosorting refers to having unprotected sex only with partners of the same positive or negative HIV status.

The researchers aimed to assess whether MSM who practice serosorting differ with regard to their risk for HIV transmission compared with non-serosorters. They administered surveys to 628 self-identified HIV negative MSM at gay pride events in June 2006 (an impressive 80% response rate).

About one-third of the survey respondents (229 men) reported that they engaged in serosorting. Men who practiced serosorting were more likely to believe that it offered protection against HIV transmission, perceived themselves to be at no relatively higher risk for HIV transmission, and had unprotected anal intercourse with more partners. More than half the men said they received HIV tests once yearly or less, and the testing frequency was similar for serosorters and non-serosorters.

“Men who identify as HIV negative and serosort are no more likely to know their HIV status than men who do not serosort and are at higher risk for exposure to HIV,” the investigators concluded. “Interventions targeting MSM must address the limitations of serosorting.”

12/11/07

Sources


G Millet, S Flores, J Peterson, and others.
Black-white disparities in HIV infection among men who have sex with men: a meta-analytic examination of HIV risk behaviors. 2007 National HIV Prevention Conference. Atlanta, GA. December 2-5, 2007. Abstract A03-1.

J Prejean, HI Hall, Q An, and others. Birth-year cohort analysis of HIV/AIDS diagnoses among MSM in 33 states, 2001-2005. 2007 National HIV Prevention Conference. Abstract B08-5.


G Millett, H Ding, J Lauby, and others.
Circumcision status and HIV infection among Black and Latino men who have sex with men in three U.S. cities. 2007 National HIV Prevention Conference. Abstract C01-4.

G Millett, H Ding, J Lauby, and others. Circumcision status and HIV infection among Black and Latino men who have sex with men in three U.S. cities. Journal of Acquired Immune Deficiency Syndromes 46(5): 643-650. December 15, 2007.

LA Eaton, SC Kalichman, DN Cain, and others.
Serosorting sexual partners and risk for HIV among men who have sex with men. American Journal of Preventive Medicine 33(6): 479-485. December 2007.
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-Approved
Treatments
Protease Inhibitors
Agenerase
Agenerase (amprenavir)
Aptivus
Aptivus (tipranavir)
Crixivan
Crixivan (indinavir)
Invirase
Invirase (saquinavir hard gel)
Kaletra
Kaletra (lopinavir/ritonavir)
Lexiva
Lexiva (fosamprenavir)
Norvir
Norvir (ritonavir)
Prezista
Prezista (darunavir)
Reyataz
Reyataz (atazanavir)
ViraceptViracept (nelfinavir)
Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
CombivirCombivir (zidovudine/lamivudine)
EpivirEpivir (lamivudine; 3TC)
EmtrivaEmtriva (emtricitabine; FTC)
EpzicomEpzicom (abacavir + lamivudine)
RetrovirRetrovir (zidovudine; AZT)
TrizivirTrizivir (abacavir + zidovudine +lamivudine)
TruvadaTruvada  (tenofovir / emtricitabine)
VidexVidex (didanosine; ddI)
VireadViread (tenofovir)
ZeritZerit (stavudine; d4T)
ZiagenZiagen (abacavir)
non Nucleoside Reverse
Transcriptase Inhibitors
RescriptorRescriptor (delavirdine)
SustivaSustiva (efavirenz)
ViramuneViramune (nevirapine)
Entry Inhibitors
(including Fusion Inhibitors)
Fuzeon (enfuvirtide, T-20)
Selzentry ( maraviroc)
Fixed-dose Combinations
AtriplaAtripla (efavirenz + emtricitabine + tenofovir)
CombivirCombivir (zidovudine + lamivudine)
TrizivirTrizivir (abacavir + zidovudine + lamivudine)
TruvadaTruvada (tenofovir + emtricitabine)